Alaunos ALN1003 Preclinical Data Show Effects on Insulin Resistance
Alaunos Therapeutics announced updated preclinical data for ALN1003, its investigational oral metabolic therapeutic candidate for obesity and related metabolic disorders. The findings from non-GLP diet-induced obesity mouse studies showed effects on insulin-resistance-related biomarkers, adipose endocrine signaling, and qualitative liver histology consistent with lower hepatic steatosis. While these early preclinical results are encouraging, the company emphasized that ALN1003 has not been evaluated in human clinical trials. Additionally, Alaunos reported cash and cash equivalents of $0.354 million as of March 31, 2026, with a cash runway extending only into the second quarter of 2026, necessitating additional financing.
Key Highlights
- Alaunos reported updated preclinical data for ALN1003, an investigational oral metabolic therapeutic candidate.
- ALN1003 showed effects on insulin-resistance-related biomarkers and adipose endocrine signaling.
- Qualitative liver histology findings were consistent with lower hepatic steatosis in DIO mouse models.
- ALN1003-treated animals had significantly lower fasting insulin and HOMA-IR (p=.0006).
- Treated samples showed lower mean NAS scores (2.7 and 1.3) compared to control samples (5).
- The company had approximately $0.354 million in cash and cash equivalents as of March 31, 2026.
- Current cash runway extends into the second quarter of 2026, with plans to pursue additional financing.
- The findings are based on non-GLP preclinical studies and have not been evaluated in human clinical trials.
Price Impact
More from TCRT